Sergio Quezada’s Programme Award to be used for Brain Tumour Therapies
Science and Innovation at Cancer Research UK shared on X:
“Sergio Quezada will use a new Programme Award to map the T-cell reactive landscape in glioblastoma multiforme to inform the development of personalised and non-personalised vaccine and cell therapies against Brain Tumours.”
Source: Science and Innovation Cancer Research UK/X
Sergio Quezada is a Professor of Cancer Immunology and Immunotherapy at the UCL Cancer Institute and Chief Scientific Officer and Co-Founder of Achilles Therapeutics Limited.
His research group at UCL investigates the precise mechanisms by which anti-CTLA-4, anti-PD-1, and other immune-modulatory antibodies target co-inhibitory and co-stimulatory pathways, including ICOS, 4-1BB, and OX-40, to develop novel anticancer therapies.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023